Bristol Myers Squibb

News

BMS’ LAG-3 RELATIVITY theory fails futility test

Bristol-Myers Squibb has abandoned a bid to extend the indications of its combination of PD-1 inhibitor Opdivo and LAG-3 inhibitor relatlimab into colorectal cancer after

News

BMS bolts on SystImmune bispecific ADC in $8.4bn deal

The litany of big-ticket deals involving antibody-drug conjugates shows no sign of ending.

News

BMS chases MSD/Seagen with first-line bladder cancer filing

The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting

News

FDA launches wide probe into CAR-T therapy safety

The FDA has announced it will start an investigation into the safety of CAR-T therapies, after becoming concerned that they may be linked to the development of T-cell canc

News

Abecma delay gives Carvykti a chance to catch up

Bristol-Myers Squibb and partner 2seventy bio are facing a delay in their attempt to bring BCMA-directed CAR-T therapy Abecma to the US market as an earlier-line therapy f

News

Bayer pulls atrial fibrillation study for asundexian

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded

BMS’ LAG-3 RELATIVITY theory fails futility test

BMS bolts on SystImmune bispecific ADC in $8.4bn deal

BMS chases MSD/Seagen with first-line bladder cancer filing

FDA launches wide probe into CAR-T therapy safety

Abecma delay gives Carvykti a chance to catch up

Bayer pulls atrial fibrillation study for asundexian

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Bristol Myers Squibb

Editor's Picks